Invesaro

Stocks Comparison

AbbVie vs Abbott Laboratories: revenue, profit, margins and growth compared

AbbVie brought in $61.2B of revenue in fiscal 2025, Abbott Laboratories $44.3B in fiscal 2025. Revenue changed by +8.6% at AbbVie and +5.7% at Abbott Laboratories on the year before, so AbbVie grew faster. AbbVie kept 6.9% of its revenue as net profit, Abbott Laboratories 14.7%. Free cash flow was $17.8B at AbbVie and $7.4B at Abbott Laboratories.

Side by side, latest fiscal year

ABBVABT
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$61.2B$44.3B
Revenue growth+8.6%+5.7%
Net income$4.2B$6.5B
Net margin6.9%14.7%
Free cash flow$17.8B$7.4B
Free cash flow margin29.1%16.7%
Earnings per share (diluted)$2.36$3.72
Cash$5.2B$8.5B
Debt$64.5B$12.9B
Price to earnings112.027.2
Market value$467.1B$175.3B
Dividend yield2.52%2.37%
Rank by revenue in sector#14 of 523 · Health care#18 of 523 · Health care

Over the years

Revenue
ABBV FY2018: $32.8BABBV FY2019: $33.3BABBV FY2020: $45.8BABBV FY2021: $56.2BABBV FY2022: $58.1BABBV FY2023: $54.3BABBV FY2024: $56.3BABBV FY2025: $61.2BABT FY2018: $30.6BABT FY2019: $31.9BABT FY2020: $34.6BABT FY2021: $43.1BABT FY2022: $43.7BABT FY2023: $40.1BABT FY2024: $42BABT FY2025: $44.3BFY18FY19FY20FY21FY22FY23FY24FY25
ABBV $61.2BABT $44.3B
Net income
ABBV FY2018: $5.7BABBV FY2019: $7.9BABBV FY2020: $4.6BABBV FY2021: $11.5BABBV FY2022: $11.8BABBV FY2023: $4.9BABBV FY2024: $4.3BABBV FY2025: $4.2BABT FY2018: $2.4BABT FY2019: $3.7BABT FY2020: $4.5BABT FY2021: $7.1BABT FY2022: $6.9BABT FY2023: $5.7BABT FY2024: $13.4BABT FY2025: $6.5BFY18FY19FY20FY21FY22FY23FY24FY25
ABBV $4.2BABT $6.5B
Net margin
ABBV FY2018: 17.4%ABBV FY2019: 23.7%ABBV FY2020: 10.1%ABBV FY2021: 20.5%ABBV FY2022: 20.4%ABBV FY2023: 9.0%ABBV FY2024: 7.6%ABBV FY2025: 6.9%ABT FY2018: 7.7%ABT FY2019: 11.6%ABT FY2020: 13.0%ABT FY2021: 16.4%ABT FY2022: 15.9%ABT FY2023: 14.3%ABT FY2024: 31.9%ABT FY2025: 14.7%FY18FY19FY20FY21FY22FY23FY24FY25
ABBV 6.9%ABT 14.7%
Revenue growth
ABBV FY2019: +1.6%ABBV FY2020: +37.7%ABBV FY2021: +22.7%ABBV FY2022: +3.3%ABBV FY2023: -6.4%ABBV FY2024: +3.7%ABBV FY2025: +8.6%ABT FY2019: +4.3%ABT FY2020: +8.5%ABT FY2021: +24.5%ABT FY2022: +1.3%ABT FY2023: -8.1%ABT FY2024: +4.6%ABT FY2025: +5.7%FY19FY20FY21FY22FY23FY24FY25
ABBV +8.6%ABT +5.7%
Free cash flow
ABBV FY2018: $12.8BABBV FY2019: $12.8BABBV FY2020: $16.8BABBV FY2021: $22BABBV FY2022: $24.2BABBV FY2023: $22.1BABBV FY2024: $17.8BABBV FY2025: $17.8BABT FY2018: $4.9BABT FY2019: $4.5BABT FY2020: $5.7BABT FY2021: $8.6BABT FY2022: $7.8BABT FY2023: $5.1BABT FY2024: $6.4BABT FY2025: $7.4BFY18FY19FY20FY21FY22FY23FY24FY25
ABBV $17.8BABT $7.4B

Fiscal years as each company reports them; the two may end in different months.

Questions about AbbVie and Abbott Laboratories

Which is bigger by revenue, AbbVie or Abbott Laboratories?

AbbVie is bigger by revenue: $61.2B in fiscal 2025, against $44.3B for Abbott Laboratories in fiscal 2025.

Which keeps more of its revenue as profit, AbbVie or Abbott Laboratories?

AbbVie had a net margin of 6.9% in fiscal 2025; Abbott Laboratories had 14.7% in fiscal 2025.

Which grew revenue faster, AbbVie or Abbott Laboratories?

In their latest fiscal years revenue changed by +8.6% at AbbVie and +5.7% at Abbott Laboratories.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies